首页 > 市场调查报告书 > 医疗设备

心血管设备循环系统

市场调查报告书

商品编码

1623006

2024 年至 2031 年心房颤动药物市场（按产品类型、应用、最终用户和地区划分）

Atrial Fibrillation Drugs Market By Product, Type, Application, End User & Region for 2024-2031

出版日期: 2024年09月25日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

心房颤动药物市场评估，2024 年至 2031 年

随着人口不断增长，尤其是老年人口，肥胖和高血压等与生活方式相关的风险因素的发生率不断上升，这加强了对早期发现和治疗的需求，为心房颤动药物市场创造了巨大的机会。根据 Verified Market Research 分析师的预测，心房颤动药物市场在 2023 年的价值预计将达到 147.8 亿美元，并在预测期内达到 199.1 亿美元的估值。

持续的研究努力专注于新的治疗技术，例如抗心律不整药物、抗凝血剂和心率控制药物的开发，将进一步增加心房颤动药物市场的扩张，使市场从 2024 年到 2031 年的复合年增长率达到 3.8%。

心房颤动药物市场：定义/概述

心房颤动药物是专门用于管理和治疗心房颤动的药物，心房颤动是一种常见的心律不整，其特征是源自心臟上腔（心房）的心律不整、心跳加速。这些药物在治疗心房颤动方面发挥多种作用，包括恢復正常心律（窦性心律）、控制心率、降低血栓和中风的风险。

此外，通常会开立抗心律不整药物来恢復规律的心跳，而控制心率药物则旨在将心率保持在正常范围内。此外，由于心房颤动患者心律不整导致血栓风险更高，因此医生通常会给他们开抗凝血剂，以防止血栓形成，降低中风的风险。

慢性病的高发性将如何影响心房颤动药物市场？

全球心房颤动盛行率的不断上升是市场发展的主要驱动力。心房颤动是最常见的严重心律不整，影响全世界数百万人，迫切需要新的治疗方法。随着人口老化以及高血压、糖尿病、肥胖等潜在疾病的盛行率增加，心房颤动的盛行率也随之增加。

全球医疗保健支出的增加，尤其是已开发经济体和新兴经济体的医疗保健支出的增加，促进了心房颤动药物市场的扩张。由于医疗保健优先考虑高品质的治疗和治疗结果，人们更加关注有效管理心房颤动等慢性病，而使用创新疗法可以改善患者的治疗结果并降低长期医疗成本。

此外，早期发现和治疗心房颤动对于预防中风和心臟衰竭等后果变得越来越重要。随着穿戴式科技和可监测心律和识别异常的行动健康应用程式的普及，早期检测也推动了市场扩张。这些努力将增加被诊断为心房颤动的人数，并扩大需要药物治疗的患者数量。

心房颤动药物的副作用对市场意味着什么？

许多用于治疗心房颤动的药物，特别是抗凝血剂，都有严重的副作用，包括出血问题。这些安全问题限制了某些药物在某些患者中的使用，并使医疗保健专业人员和患者对药物治疗心房颤动犹豫不决，从而限制了市场的成长。

当心房颤动市场关键药物的专利到期时，仿製药的竞争就会出现，从而大大减少原厂药製造商的收入。仿製药虽然降低了药品价格，但也对市场构成了课题，因为它降低了投资创新和新药研究的动力。

此外，儘管心房颤动在全球流行，但由于成本高、医疗基础设施缺乏以及医疗服务提供者和患者缺乏认识，许多新兴国家仍然无法获得现代治疗选择，包括现代抗凝血剂。社会经济因素和医疗保健系统的差异进一步加剧了这项课题，阻碍了这些地区心房颤动药物市场的扩张。

Rising rates of lifestyle-related risk factors such as obesity and hypertension among the growing population, especially geriatric populace, is bolstering the demand for early detection and treatment, creating immense opportunities for Atrial Fibrillation Drugs Market. According to the analyst from Verified Market Research, the Atrial Fibrillation Drugs Market is estimated to reach a valuation of USD 19.91 Billion over the forecast subjugating aroundUSD 14.78 Billion valued in 2023.

Ongoing research efforts focusing on novel therapeutic techniques, such as the development of anti-arrhythmic medicines, anticoagulants, and rate control pharmaceuticals, are further increasing Atrial Fibrillation Drugs Market expansion and enabling the market to grow at aCAGR of 3.8% from 2024 to 2031.

Atrial Fibrillation Drugs Market: Definition/ Overview

Atrial fibrillation drugs are medications that are specifically intended to manage and treat atrial fibrillation, a common heart rhythm disease characterized by irregular and fast heartbeats that originate in the heart's upper chambers (atria). These medications perform a variety of functions in the treatment of atrial fibrillation, including restoring normal heart rhythm (sinus rhythm), managing heart rate, and lowering the risk of blood clots and stroke.

Furthermore, anti-arrhythmic drugs are commonly prescribed to assist restore a regular heart rhythm, whereas rate control medications try to keep the heart rate within normal limits. Also, anticoagulant drugs are often prescribed to prevent blood clot development and lower the risk of stroke, as people with atrial fibrillation have a higher risk of blood clots due to their irregular heartbeat.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How will High Prevalence of Chronic Illnesses Affect the Atrial Fibrillation Drugs Market?

The growing prevalence of atrial fibrillation around the world is a significant driver of the market. Atrial fibrillation is the most frequent type of severe arrhythmia, affecting millions of people globally, increasing the need for new treatment alternatives. Ageing populations, as AFib incidence rises with age, as well as rising rates of underlying diseases such as hypertension, diabetes, and obesity, all contribute to rising prevalence.

Increased global healthcare spending, particularly in developed and emerging economies, contributes to the expansion of the Atrial Fibrillation Drugs Market. With healthcare systems prioritizing quality care and outcomes, there is a greater emphasis on the effective management of chronic illnesses such as atrial fibrillation This involves the use of innovative treatment alternatives, which can improve patient outcomes and lower long-term healthcare expenditures.

Furthermore, early identification and treatment of atrial fibrillation are becoming increasingly important in preventing consequences such as stroke and heart failure. Early detection through the widespread use of wearable technology and mobile health apps that can monitor cardiac rhythms and identify anomalies also helps to drive market expansion. These initiatives increase the number of people diagnosed with atrial fibrillation, which broadens the patient pool that requires drug therapy.

What will Side Effects of Atrial Fibrillation Drugs have on the Market?

Many drugs used to treat atrial fibrillation, particularly anticoagulants, are associated with substantial side effects, such as bleeding problems. These safety concerns limit the use of specific medications in particular patients cause healthcare practitioners and patients to be hesitant about managing atrial fibrillation pharmacologically, and limiting market growth.

The expiration of patents for important medications in the atrial fibrillation market allows for generic competition, substantially decreasing revenue for pharmaceutical companies that produced the original branded drugs. While generics make drugs more affordable, they also pose a challenge to the market by reducing incentives for innovation and investment in new medication research.

Furthermore, despite the global prevalence of atrial fibrillation, many emerging economies still have limited access to modern treatment options, including the most recent anticoagulants, due to high costs, a lack of healthcare infrastructure, and a lack of awareness among healthcare providers and patients. This difficulty is exacerbated by socioeconomic reasons and differences in healthcare systems, which impede the expansion of the atrial fibrillation medication market in these locations.

Category-Wise Acumens

What are the Drivers that Contribute to the Demand for the Anticoagulant segment?

According to VMR analysis, the anticoagulant drugs segment is estimated to hold the largest market share during the forecast period. The global growth in atrial fibrillation prevalence has led to an increase in the demand for better stroke prevention methods. Anticoagulant medications, particularly NOACs, are the cornerstone of stroke prevention in atrial fibrillation patients, which contributes to their market dominance. The emphasis on lowering the risk of stroke in atrial fibrillation patients with appropriate anticoagulant medication contributes to the segment's sustained expansion and dominance.

Novel Oral Anticoagulants (NOACs) have been proven to be as effective as or more effective than Vitamin K Antagonists (VKAs) such as warfarin, with a better safety profile, particularly in terms of lowering the risk of significant bleeding problems. NOACs also have less food-drug interactions than VKAs, making them a more convenient choice for patients. This increased efficacy and safety profile has resulted in a high preference for NOACs among healthcare providers and patients, contributing to the anticoagulant drug segment's dominance.

Furthermore, clinical recommendations from top cardiology and thrombosis associations throughout the world increasingly advocate NOACs over VKAs for the majority of AFib patients due to their favorable benefit-risk profile. These guidelines have an impact on prescribing practices and have played a crucial role in the broad adoption of NOAC. The robust endorsement by clinical guidelines assures that NOACs continue their leading position in the anticoagulant drug market.

What are the Potential Factors for the Dominance of Paroxysmal Type in the Market?

The paroxysmal segment is estimated to dominate the Atrial Fibrillation Drugs Market during the forecast period. Paroxysmal Atrial Fibrillation, which is characterized by the abrupt start of irregular heartbeats that stop within seven days (typically resolving within 24 hours), is common since it is frequently the first phase of atrial fibrillation in many people. Drugs aimed at this segment are in more demand because of their episodic character, which often makes it the first kind of atrial fibrillation to be recognized and treated.

Paroxysmal atrial fibrillation is generally treated with a combination of medicines, ranging from anticoagulants to prevent strokes to antiarrhythmic drugs to regulate rhythm. This variety of treatment alternatives can help the segment get a greater market share because it includes a wide range of pharmaceuticals that can be adapted to particular patient needs, as well as newer and more advanced pharmacological breakthroughs.

Furthermore, effectively managing paroxysmal atrial fibrillation can stop or slow the development of more chronic and persistent forms of the condition, which are more difficult to treat and have a higher risk of problems. This therapeutic potential supports a high emphasis on early and effective treatment techniques, including medication therapies, which contributes to the segment's dominance in the Atrial Fibrillation Drugs Market.

Country/Region-wise Acumens

What are the Factors that Contribute to North America's Competitive Edge in the Market?

According to VMR analyst, North America is estimated to dominate the Atrial Fibrillation Drugs Market during the forecast period. North America, particularly the United States, has a high frequency of cardiovascular disorders, including atrial fibrillation, which is caused by variables such as ageing populations, lifestyle choices, and obesity. This results in a large patient pool requiring atrial fibrillation treatment, which fuels demand for atrial fibrillation drugs.

The region has advanced healthcare systems that provide extensive access to cutting-edge medical technology and treatments. This infrastructure promotes early diagnosis, treatment innovation, and successful management of atrial fibrillation, resulting in higher acceptance rates of innovative atrial fibrillation medications than other locations.

Furthermore, North America is a pharmaceutical research and development hotspot, with a significant emphasis on innovative drug therapies. The presence of major pharmaceutical companies, as well as significant investment in R&D activities, help to accelerate the release of novel and effective atrial fibrillation medications, boosting market expansion in the region.

Will Flourishing Healthcare Infrastructure in Asia Pacific Boom Atrial Fibrillation Drugs Market?

Asia Pacific region is estimated to exhibit the highest growth in the market during the forecast period. Asia Pacific is experiencing a substantial demographic shift, with increasing ageing populations, particularly in Japan and China. Older age is a significant risk factor for atrial fibrillation, resulting in an increasing patient population in need of atrial fibrillation treatments and driving demand for atrial fibrillation medications in the region.

This region is experiencing significant advances in healthcare infrastructure and increased healthcare spending. Countries are investing in better healthcare infrastructure and treatment access, making modern atrial fibrillation medications more accessible to the general public, hence driving market expansion.

Furthermore, in the Asia-Pacific region, there is growing awareness of atrial fibrillation and associated complications. When combined with increased healthcare access and insurance coverage, this leads to higher diagnostic rates and treatment uptake, driving the expansion of the Atrial Fibrillation Drugs Market.

Competitive Landscape

The competitive landscape of the Atrial Fibrillation Drugs Market is marked by fierce competition among several players vying for a significant market share. In addition, market participants frequently pursue strategic partnerships, collaborations, and acquisitions to boost their market position and broaden their product ranges.

Some of the prominent players operating in the Atrial Fibrillation Drugs Market include:

Abbott Laboratories, Bristol-Myers Squibb, Johnson & Johnson, Pfizer Inc., Novartis AG, Hoffmann-La Roche Ltd, Sanofi S.A., Merck & Co., Inc., Daiichi Sankyo Company, Limited, Boehringer Ingelheim GmbH, AstraZeneca PLC, Bayer AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Medtronic plc, Shionogi & Co., Ltd., Astellas Pharma Inc., Meda Pharmaceuticals, and Cardionomic Therapeutics Inc.

Latest Developments

In October 2023, Bristol-Myers Squibb announced favorable findings from the Phase 3 PEACH-AF trial. The experiment assessed the efficacy and safety of the investigational medication, lixisenatide, in preventing stroke in individuals with AF.

In September 2023, Pfizer Inc. announced a collaboration with Apple to create a new wearable device that can detect and monitor AF via a person's smartphone.

In April 2023, Johnson & Johnson presented results at the American College of Cardiology meeting that demonstrated the long-term safety and efficacy of their medicine, Edoxaban, in avoiding stroke in patients with AF.

1 INTRODUCTION OF GLOBAL ATRIAL FIBRILLATION DRUGS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model

5 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY PRODUCT

5.1 Overview
5.2 Antiarrhythmic Drug
5.3 Anticoagulant Drugs
- 5.3.1 Vitamin K Antagonists
- 5.3.2 Novel Oral Anticoagulants

6 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY TYPE

6.1 Overview
6.2 Paroxysmal
6.3 Persistent
6.4 Permanent

7 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY APPLICATION

7.1 Overview
7.2 Heart Rhythm Control
7.3 Heart Rate Control

8 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY END USER

8.1 Overview
8.2 Hospitals
8.3 Cardiac Centers
8.4 Ambulatory Surgical Centers

9 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe & Africa
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East & Africa

10 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11 COMPANY PROFILES

11.1 Abbott Laboratories
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Bristol-Myers Squibb
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Johnson & Johnson
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Pfizer Inc.
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 Novartis AG
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 F. Hoffmann-La Roche Ltd
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 Sanofi S.A.
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Merck & Co., Inc.
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11. 9 Daiichi Sankyo Company, Limited
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 Boehringer Ingelheim GmbH
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments